SOS1和KSR1调节MEK抑制剂对基于PI3K和KRAS突变状态的耐药细胞群的反应反应
Brianna R Daley1, Heidi M Vieira2, Chaitra Rao2
1Department of Pharmacology and Molecular Therapeutics, Uniformed Services University of the Health Sciences, Bethesda, MD 20814.
概括
向SOS1或KSR1使用特拉美丁尼布可以克服KRAS突变癌症的耐药性. 删除KSR1恢复了敏感性,而PIK3CA的交换限制了SOS1抑制的有效性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 癌症治疗方法 癌症治疗方法
背景情况:
- KRAS突变在癌症中很常见,驱动RAF/MEK/ERK等信号通路.
- 目前的向疗法面临内在和获得的耐药性,通常是由于持续性细胞或RTK/RAS重新激活.
- 了解抵抗机制对于开发有效的癌症治疗至关重要.
研究的目的:
- 调查SOS1或KSR1的向是否可以提高MEK抑制剂的疗效,并预防KRAS突变癌症的耐药性.
- 为了确定PIK3CA转换对组合疗法的疗效的影响.
- 评估KSR1作为克服治疗耐药性的潜在目标.
主要方法:
- 使用KRAS突变的肺腺癌 (LUAD) 和结直肠腺癌 (COAD) 细胞系.
- 测试了MEK抑制剂特拉美替尼与SOS1抑制剂BI-3406.6的联合治疗.
- 评估了KSR1删除对药物敏感性和球状启动细胞 (SIC) 种群的影响.
- 分析了基于特定KRAS突变和PIK3CA突变的响应.
主要成果:
- 通过向SICs,BI-3406与特拉美替尼布结合增强了KRAS突变的LUAD/COAD缺乏PIK3CA转换的疗效,并防止了耐药性.
- 具有PIK3CA突变的KRAS突变细胞系对美替尼和BI-3406组合不敏感.
- 删除KSR1阻止了药物诱导的SIC上调,并在所有测试的KRAS突变细胞系中恢复了特拉美替尼的敏感性,无论PIK3CA状态如何.
结论:
- 垂直抑制RTK/RAS信号传递是对抗KRAS突变癌症的可行策略.
- 治疗疗效取决于特定的KRAS突变和PIK3CA等同时发生的突变.
- 向KSR1显示了克服KRAS突变癌症中特拉美丁尼布抗性的广泛潜力,而SOS1抑制则取决于上下文.
相关概念视频
PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
The Ras Gene
6.2K
The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
Ras is a...
6.2K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
MAPK Signaling Cascades
5.6K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.6K
Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K


